Woodline Partners LP Igm Biosciences, Inc. Transaction History

Woodline Partners LP

$11 Billion
Q3 2024

A detailed history of Woodline Partners LP transactions in Igm Biosciences, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 67,259 shares of IGMS stock, worth $679,315. This represents 0.01% of its overall portfolio holdings.

Number of Shares

67,259

Previous 75,000 10.32%

Holding current value

$679,315

Previous $515,000 115.92%

% of portfolio

0.01%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$6.28 - $17.68 $48,613 - $136,860	-7,741 Reduced 10.32%	67,259 $1.11 Million
Q2 2023 Aug 14, 2023	SELL	$8.86 - $14.0 $698,389 - $1.1 Million	-78,825 Reduced 51.24%	75,000 $692,000
Q1 2023 May 15, 2023	BUY	$13.74 - $25.76 $52,555 - $98,532	3,825 Added 2.55%	153,825 $2.11 Million
Q4 2022 Feb 14, 2023	SELL	$15.45 - $26.02 $773,226 - $1.3 Million	-50,047 Reduced 25.02%	150,000 $2.55 Million
Q2 2022 Aug 15, 2022	SELL	$13.27 - $25.5 $2.7 Million - $5.19 Million	-203,354 Reduced 50.41%	200,047 $3.61 Million
Q4 2021 Feb 14, 2022	SELL	$27.59 - $66.39 $4.57 Million - $11 Million	-165,608 Reduced 29.1%	403,401 $11.8 Million
Q3 2021 Nov 15, 2021	SELL	$65.76 - $90.65 $11.6 Million - $16 Million	-176,384 Reduced 23.66%	569,009 $37.4 Million
Q2 2021 Aug 16, 2021	BUY	$57.98 - $96.6 $18.2 Million - $30.4 Million	314,710 Added 73.07%	745,393 $62 Million
Q1 2021 May 17, 2021	SELL	$71.56 - $121.23 $7.85 Million - $13.3 Million	-109,733 Reduced 20.31%	430,683 $33 Million
Q4 2020 Feb 16, 2021	BUY	$47.41 - $115.03 $21.3 Million - $51.8 Million	450,038 Added 497.95%	540,416 $47.7 Million
Q3 2020 Nov 16, 2020	BUY	$43.0 - $84.01 $3.89 Million - $7.59 Million	90,378 New	90,378 $6.67 Million

Others Institutions Holding IGMS

# of Institutions

Shares Held

20.7M

Call Options Held

56.9K

Put Options Held

52.2K

View Full List

About IGM Biosciences, Inc.

Ticker IGMS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,969,000
Market Cap $293M
Description
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...

More about IGMS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.

Account

Woodline Partners LP Igm Biosciences, Inc. Transaction History